Rational Use of Recombinant Factor VIIa in Clinical Practice

Review Article


In the United States, the FDA-approved indications for recombinant factor VIIa is for bypassing inhibitors to factors VIII and IX in patients with hemophilia A and B respectively and for treatment of congenital factor VII deficiency. In European countries, rFVIIa is licensed for the above indications as well as for Glanzmann’s thrombasthenia. In absence of high-quality data favoring off-label use of this agent and laboratory test to predict response to this agent, and in view of high cost of rFVIIa, off-label use of recombinant factor VIIa should be restricted to only when hemorrhage has not responded to transfusion or other conventional therapy. It appears, two such conditions where recombinant factor VIIa may be beneficial are traumatic and postpartum hemorrhages.


Recombinant Factor VIIa (rFVIIa) Hemophilia with inhibitors Postpartum hemorrhage 


  1. 1.
    Hedner U (2006) Mechanism of action of Factor VIIa in the treatment of coagulopathies. Semin Thromb Hemost 32(Supp 1):77–85PubMedCrossRefGoogle Scholar
  2. 2.
    Lindley CM, Sawyer WT, Maick BG, Lusher J, Harrison JF, Baird-Cox K et al (1994) Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 55:638–648PubMedCrossRefGoogle Scholar
  3. 3.
    Ehrenforth S, Kreuz W, Scharrer I et al (1992) Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 339:594–598PubMedCrossRefGoogle Scholar
  4. 4.
    Kessler CM (2000) New products for managing inhibitors to coagulation factors: a focus on recombinant factor VIIa concentrate. Curr Opin Hematol 7:408–413PubMedCrossRefGoogle Scholar
  5. 5.
    Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA (1998) Prospective randomized trial of two doses of r-FVIIa in hemophilia patients with inhibitors undergoing surgery. Thromb Haemost 80:773–778PubMedGoogle Scholar
  6. 6.
    d`Oiron R, Menart C, Trzeciak MC et al (2000) Use of rFVIIa in 3 patients with inherited type 1 Glanzmanns Thrombasthenia undergoing invasive procedures. Thromb Haemost 83:644–647Google Scholar
  7. 7.
    Mariani G, Testa MG, Piolantonio TD, Molskov RB, Hedner U (1999) Use of recombinant activated FVIIa in the treatment of congenital factor VII deficiencies. Vox Sang 77:131–136PubMedCrossRefGoogle Scholar
  8. 8.
    Logan AC, Yank V, Stafford RS (2011) Off-label use of recombinant factor VIIa in US hospitals: analysis of hospital records. Ann Intern Med 154(8):516–522PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Kenet G, Walden R, Eldad A, Martinowitz U (1999) Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 354:1879PubMedCrossRefGoogle Scholar
  10. 10.
    Mauricio L, Jeroukhimov I, Klein Y, Martinowitz U (2002) Updates in the management of severe coagulopathy in trauma patients. Intensive Care Med 28:S241–S247CrossRefGoogle Scholar
  11. 11.
    Boffard KD, Riou B, Warren B et al (2005) Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo controlled, double blind clinical trials. J Trauma 59(1):8–15PubMedCrossRefGoogle Scholar
  12. 12.
    Knudson MM, Cohen MJ, Reidy R et al (2011) Trauma, transfusions, and use of recombinant factor VIIa: a multicenter case registry report of 380 patients from the Western Trauma Association. J Am Coll Surg 212:87–95PubMedCrossRefGoogle Scholar
  13. 13.
    Friederich PW, Henny CP, Messelink EJ et al (2003) Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double–blind placebo-controlled randomised trial. Lancet 361:201–205PubMedCrossRefGoogle Scholar
  14. 14.
    Gill R, Herbertson M, Vuylsteke A et al (2009) Safety and efficacy of recombinant activated factor VII: a placebo controlled trial in the setting of bleeding after cardiac surgery. Circulation 120:21–27PubMedCrossRefGoogle Scholar
  15. 15.
    Hendriks HG, Meijer K, de Wolf JT et al (2001) Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study. Transplantation 71:402–405PubMedCrossRefGoogle Scholar
  16. 16.
    Ranucci M, Isgro G, Soro G et al (2008) Efficacy and safety of recombinant activated factor VII in major surgical procedures: systematic review and meta-analysis of randomized clinical trials. Arch Surg 143:296–304PubMedCrossRefGoogle Scholar
  17. 17.
    Shailesh RS, Evita F, Sunil TP, Badrinath HR (2009) Recombinant VIIa: use in fatal postpartum hemorrhage—Indian experience case series and review of literature. Indian J Hematol Blood Transfus 25(1):1–5CrossRefGoogle Scholar
  18. 18.
    Franchini M, Franchi M, Bergamini V et al (2010) The use of recombinant activated FVII in postpartum hemorrhage. Clin Obstet Gynaecol 53(1):219–227CrossRefGoogle Scholar
  19. 19.
    Mayer SA, Brun NC, Begtrup K, Broderick J et al (2005) Recombinant activated factor VII for acute intracerebral hemorrhage. NEJM 352:777–785PubMedCrossRefGoogle Scholar
  20. 20.
    Mayer SA, Brun NC, Begtrup K, Broderick J et al (2008) Efficacy and safety of recombinant activated factor VII for acute cerebral hemorrhage. NEJM 358:2127–2137PubMedCrossRefGoogle Scholar
  21. 21.
    Deveras RA, Kessler GM (2002) Reversal of warfarin induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med 137:884–888PubMedCrossRefGoogle Scholar
  22. 22.
    Hsia CC, Chin-Yee IH, McAlister VC (2008) Use of recombinant activated factor VII in patients without hemophilia: a meta-analysis of randomized control trials. Ann Surg 248:61–68PubMedCrossRefGoogle Scholar
  23. 23.
    Yank V, Tuohy CV, Logan AC et al (2011) Systematic review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. Ann Intern Med 154:529–540PubMedCrossRefGoogle Scholar
  24. 24.
    Biss TT, Hanley JP (2007) Use of recombinant factor VIIa in the management of intractable hemorrhage: a survey of current UK practice. Br J Haematol 138:126–128PubMedCrossRefGoogle Scholar
  25. 25.
    Allen GA, Hoffman M, Roberts HR, Monroe DM 3rd (2002) Recombinant activated factor VII: its mechanism of action and role in control of hemorrhage. Can J Anaesth 49:S7–S14PubMedGoogle Scholar
  26. 26.
    Goodnough LT, Lumbin DM, Zhang L et al (2004) Transfusion medicine service policies for recombinant factor VIIa administration. Transfusion 44:1325–1331PubMedCrossRefGoogle Scholar
  27. 27.
    O’Connell KA, Wood JJ, Wise RP et al (2006) Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 295:293–298PubMedCrossRefGoogle Scholar

Copyright information

© Indian Society of Haematology & Transfusion Medicine 2013

Authors and Affiliations

  1. 1.Division of Clinical Hematology, Department of MedicineJawaharlal Institute of Postgraduate Medical Education & ResearchPuducherryIndia

Personalised recommendations